BrainStorm Cell Therapeutics halfway through enrolling its Phase 3 ALS study

BrainStorm Cell Therapeutics (NASDAQ:BCLI) CMO Dr. Ralph Kern sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Upcoming Events

10/04-06/23
01/08-10/24
01/08-10/24
01/08-10/24
01/08-10/24
07/15-17/24